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Optimization of human serum albumin monoliths for chiral
separations and high-performance affinity chromatography
Erika L. Pfaunmiller, Mahli Hartmann, Courtney M. Dupper, Sony Soman, and David S.
Hage*
Chemistry Department, University of Nebraska, Lincoln, NE, USA

Abstract
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Various organic-based monoliths were prepared and optimized for immobilization of the protein
human serum albumin (HSA) as a binding agent for chiral separations and high-performance
affinity chromatography. These monoliths contained co-polymers based on glycidyl methacrylate
(GMA) and ethylene glycol dimethacrylate (EDMA) or GMA and trimethylolpropane
trimethacrylate (TRIM). A mixture of cyclohexanol and 1-dodecanol was used as the porogen,
with the ratio of these solvents being varied along with the polymerization temperature to generate
a library of monoliths. These monoliths were used with both the Schiff base and epoxy
immobilization methods and measured for their final content of HSA. Monoliths showing the
highest protein content were further evaluated in chromatographic studies using R/S-warfarin and
D/L-tryptophan as model chiral solutes. A 2.6–2.7-fold increase in HSA content was obtained in the
final monoliths when compared to similar HSA monoliths prepared according to the literature.
The increased protein content made it possible for the new monoliths to provide higher retention
and/or two-fold faster separations for the tested solutes when using 4.6 mm i.d. × 50 mm columns.
These monoliths were also used to create 4.6 mm i.d. × 10 mm HSA microcolumns that could
separate the same chiral solutes in only 1.5–6.0 min. The approaches used in this study could be
extended to the separation of other chiral solutes and to the optimization of organic monoliths for
use with additional proteins as binding agents.

Keywords
Monolith columns; Human serum albumin; High-performance affinity chromatography; Chiral
separations; Affinity monolith chromatography
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1. Introduction
Monolithic columns have been of great recent interest for use in high-performance affinity
chromatography (HPAC) because of their low back pressures, ease of preparation and good
mass transfer properties [1–10]. The combination of affinity ligands with monolith columns
is also known as affinity monolith chromatography (AMC) [4,11–14]. Both HPAC and
AMC rely on the use of an immobilized binding agent (i.e., the affinity ligand) for the
selective separation or analysis of substances in complex samples, including applications
that involve chiral separations [3–6,13,14,16–23]. One protein that has been often used in
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these methods for chiral separations and to study drug-protein interactions is human serum
albumin (HSA), which can retain a variety of drugs and small organic solutes with
moderately strong binding [5,16–22]. Alternative ligands that have been used in monoliths
for chiral separations include bovine serum albumin and α1-acid glycoprotein [3,18–22].
The advantages of using HPAC or AMC for chiral separations include their selectivity, ease
of automation, high specificity, speed, and good reproducibility [1–8]. However, in
preparing columns for this work it is important to consider the way in which the affinity
ligand is attached to the support and the total amount of ligand that is present, especially if
good retention and resolution are desired between the retained sample components [4,5].
Various types of support materials have been employed in AMC, with many reports using
monoliths that contain co-polymers of glycidyl methacrylate (GMA) and ethylene glycol
dimethacrylate (EDMA) (i.e., the functional monomer and cross-linking agent, respectively)
[1–8]. The co-solvents utilized to prepare these monoliths are usually cyclohexanol and 1dodecanol, which are responsible for pore formation during polymerization. It has been
shown previously that GMA/EDMA monoliths can be used to immobilize proteins such as
HSA for use in chiral separations or antibodies, lectins and protein A for use in HPAC [3–
6,11,13]. An alternative cross-linking agent that is sometimes used in place of EDMA is
trimethylolpropane trimethacrylate (TRIM), as has been used with GMA to prepare
monoliths for normal-phase separations of N-glycans [15].
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This study will use a combinatorial approach to optimize the total amount of protein that can
be immobilized to monolithic supports for HPAC and AMC based on either GMA/EDMA
or GMA/TRIM. HSA will be the affinity ligand and chiral stationary phase examined in this
report. Factors to be considered will include the monomer and porogen composition of the
polymerization mixture, as well as the temperature that is used for thermal-initiated
polymerization. The resulting supports will be used with two immobilization techniques
(i.e., the epoxy method and Schiff base method) and evaluated in terms of the total amount
of HSA that can be placed within each monolith. Imaging techniques will be utilized to
compare the overall morphology of these materials, and zonal elution studies will be used to
compare the retention and stereoselectivity of these materials for model chiral solutes. The
results should make it possible to create columns for HPAC and AMC that have higher
retention or resolution for applications such as chiral separations.

2. Experimental
2.1. Reagents
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The GMA (97% pure), EDMA (98%), cyclohexanol (>99%), 1-dodecanol (98%), 2,2′azoisobutyronitrile (AIBN, 98%), TRIM (98%), 1-propanol (>99.5%), HSA (Cohn fraction
V, essentially fatty acid free, ≥96%), sodium cyanoborohydride (94%, a mild reducing
agent), sodium borohydride (98%, a strong reducing agent), periodic acid (>99%, an
oxidizing agent), racemic warfarin (3-(α-acetonylbenzyl)-4-hydroxycoumarin, >98%) and D/
L-tryptophan (>98%) were from Sigma–Aldrich (St. Louis, MO, USA). Reagents for the
bicinchoninic acid (BCA) protein assay were from Pierce (Rockford, IL, USA). All buffers
and aqueous solutions were prepared using water from a Nanopure system (Barnstead,
Dubuque, IA, USA) and were filtered using 0.2 μm GNWP nylon filters from Millipore
(Billerica, MA, USA).
2.2. Apparatus
Some of the monoliths were prepared in 4.6 mm i.d. × 50 mm or 10 mm long stainless steel
columns with PEEK inner liners from All-tech (Deerfield, IL, USA). These columns
included a special frit that could be used to compress the monoliths and avoid the formation
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of gaps within the columns during and after their preparation. These columns were used with
the final optimized HSA monoliths for chiral separations and to compare their results with
similar monoliths prepared according to previous methods [5]. The remainder of the
monoliths were prepared in 4.6 mm i.d. × 1 mm PEEK disks [3]. These disk columns were
used during studies examining the effect of monolith preparation conditions on the amount
of HSA that could be placed within such supports. The immobilization of HSA within the
monoliths was accomplished through the use of a reciprocating Waters 501 HPLC pump
from Millipore (Milford, MA, USA) [3,5].
The HPLC system used in the chromatographic studies consisted of a model 200 gradient
pump and model 200 absorbance detector from Perkin Elmer (Waltham, MA, USA).
Samples were injected using a Rheodyne Lab Pro valve (Cotati, CA, USA) and a 20 μL loop
constructed from PEEK tubing. Chromatographic data were collected using LabView 5.1
(National Instruments, Austin, TX, USA) and processed using PeakFit 4.12 (SeaSolve
Software, San Jose, CA, USA). Scanning electron microscopy (SEM) was performed in the
Beadle Center at the University of Nebraska (Lincoln, NE, USA) by using a Hitachi S4700
field-emission scanning electron microscope with a W95/NT-based computerized operating
system (Pleasanton, CA, USA).
2.3. Preparation of monoliths
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The general reaction scheme used for the preparation of the monolith columns has been
described previously [3,5]. There were two types of monoliths prepared, as indicated in Fig.
1. The first type, shown at the top of Fig. 1, consisted of a mixture of GMA and EDMA that
was prepared in either a 50:50 (v/v) ratio that was polymerized at 60 °C or in a 60:40 (v/v)
ratio that was polymerized at 80 °C. These mixtures and temperatures were chosen because
similar conditions have been used in prior work for the preparation of GMA/EDMA
columns for the immobilization of immunoglobulin G (IgG), HSA, and trypsin [3,5,7]. The
GMA and EDMA were combined with various amounts of cyclohexanol and 1-dodecanol
(i.e., the porogenic solvents). The amount of GMA/EDMA compared to the porogen mixture
was held constant at 40:60 (v/v). This meant the overall content of GMA and EDMA was
20% and 20% (v/v) in the mixture that was polymerized at 60 °C, or 24% and 16% in the
mixture that was polymerized at 80 °C. AIBN was used as a thermal initiator and was
present at a level equal to 1% (w/w) of the total amount of GMA and EDMA in the
polymerization mixture.

NIH-PA Author Manuscript

The second type of monolith that was examined was based on GMA/TRIM, as illustrated at
the bottom of Fig. 1. This type of monolith was prepared using a ratio of GMA to TRIM of
70:30 (v/v), as has been employed for other GMA/TRIM columns [8]. Cyclohexanol and 1dodecanol were again used as the porogenic solvents, with the relative amount of these
solvents being varied to alter the pore size and morphology of the corresponding monoliths.
The amount of GMA/TRIM compared to the porogen was again held constant at 40:60 (v/v),
giving 28% GMA and 12% TRIM (v/v) in the overall mixture. The amount of AIBN was
1% (w/w) of the total amount of GMA and EDMA in the polymerization mixture. The
polymerization of these materials was carried out at either 60 °C or 80 °C.
Prior to polymerization, each mixture of reagents was combined in a flask and sonicated for
10 min. A stream of nitrogen was passed through the flask for 15 min to remove any air
bubbles. A 1 mL syringe was used to place the polymerization mixture into a 4.6 mm i.d. ×
50 mm or a 4.6 mm i.d. × 10 mm PEEK-lined column housing or into a vial containing four
to six 4.6 mm i.d. × 1 mm PEEK disks. When using the PEEK-lined columns, one end of the
column was sealed with a plug prior to the addition of reagents, with a second plug being
added to the other end once the column had been filled. The 4.6 mm i.d. × 50 mm columns
and the 4.6 mm i.d. × 10 mm columns were held upright in a sonicator for 5 min to remove
J Chromatogr A. Author manuscript; available in PMC 2013 December 21.
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any air bubbles prior to placing the columns in a water bath at either 60 °C or 80 °C for 24 h.
After polymerization of the monoliths in the 4.6 mm i.d. × 50 mm and the 4.6 mm i.d. × 10
mm columns, a special frit-insert was used to compress the monolith against the wall and to
reduce the effects of polymer shrinkage. For the 4.6 mm i.d. × 1 mm disks, a Delrin housing
and PEEK-lined frits were used to place each monolith into a column. After the columns
were assembled, they were washed with acetonitrile for 2 h at 0.5 mL/min and room
temperature, followed by a 1 h wash with water at the same flow rate.
2.4. Protein immobilization
The procedure employed for the immobilization of HSA by the Schiff base method is
depicted in Fig. 2(a) and was carried out according to a previously-reported method [5]. This
method involved the hydrolysis of the GMA/EDMA monolith epoxy groups to diol groups
through the addition of a mild aqueous solution of sulfuric acid, followed by oxidation of the
diol groups with periodic acid to form aldehydes. These aldehyde groups were then reacted
with primary amine groups on HSA to form a reversible Schiff base. The Schiff base was
converted upon formation to a more stable secondary amine through the use of a mild
reducing agent such as sodium cyanoborohydride. Any unreacted aldehydes were later
converted into alcohol groups through the addition of sodium borohydride.
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To carry out the Schiff base method with the monolith columns, a 5 mL solution of 0.5 M
sulfuric acid was passed through the column at 0.5 mL/min. The column was sealed and
placed in a water bath at 60 °C for 4 h. The column was then removed from the water bath
and washed with 100 mL water at 0.5 mL/min. A 40 mL solution containing 2 g periodic
acid in a 90:10 (v/v) mixture of acetic acid and water was circulated and recycled through
the column for approximately 4 h at 0.5 mL/min and room temperature, followed by a wash
with 100 mL water at 0.5 mL/min. Next, for the disk columns a 10 mL solution of 5 mg/mL
HSA in pH 6.0, 1.5 M potassium phosphate buffer, which also contained 25 mg sodium
cyanoborohydride, was circulated and recycled through each disk at 0.5 mL/min for 3 days
at room temperature. This step was followed by the application of a fresh 10 mL portion of
the HSA and sodium cyanoborohydride solution, which was applied to the same column at
0.5 mL/min for an additional 3 days at room temperature. A 20 mL solution containing 2.5
mg/mL of sodium borohydride in pH 8.0, 0.1 M potassium phosphate buffer was applied to
the column in a circulating manner for 2 h at 0.5 mL/min and room temperature. The
column was then washed with pH 7.4, 0.067 M potassium phosphate buffer for 4 h at 0.5
mL/min and room temperature. The column was stored in the pH 7.4, 0.067 M phosphate
buffer at 4 °C until use.
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The procedure for the Schiff base immobilization of HSA onto the 4.6 mm i.d. × 50 mm
columns and the 4.6 mm i.d. × 10 mm columns was carried out in the same manner as
described for the disk columns but used a 20 mL solution of 10 mg/mL HSA in pH 6.0, 1.5
M potassium phosphate buffer, which also contained 100 mg of sodium cyanoborohydride
and which was circulated and recycled through the column at 0.5 mL/min for 3 days at room
temperature. This immobilization step was repeated for an additional 3 days with a fresh 20
mL portion of the HSA and sodium cyanoborohydride solution in pH 6.0, 1.5 M phosphate
buffer. The remaining steps were the same as described for the disk columns.
The reactions for the epoxy immobilization method are shown in Fig. 2(b). This approach
was also adapted from a previously-reported method [3,5]. This method involved the
nucleophilic attack by a primary amine group present on HSA with an epoxy group on the
monolith, leading to the base opening of these groups to generate a stable secondary amine
linkage. In this study, this immobilization was carried out by circulating and recycling a 10
mL solution containing 6 mg/mL HSA in pH 8.0, 1.5 M potassium phosphate buffer through
the monolith for 3 days at room temperature and 0.5 mL/min. After 3 days, a fresh portion
J Chromatogr A. Author manuscript; available in PMC 2013 December 21.
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of the same type of HSA solution was passed through the column for an additional 3 days at
room temperature. After the immobilization step, any remaining epoxy groups were blocked
by passing through the column 60 mL of pH 8.0, 0.2 M Tris buffer at 0.5 mL/min for 2 h at
room temperature [5]. The column was then washed for 4 h with pH 7.4, 0.067 M potassium
phosphate buffer at 0.5 mL/min and stored in the same buffer at 4 °C until use.
2.5. Assessment of monoliths
The total amount of HSA that was present in each type of monolith after immobilization was
measured by using a BCA assay [24]. For the BCA assay, each 4.6 mm i.d. × 1 mm disk
monolith containing immobilized HSA was prepared in triplicate and washed with 100 mL
water at 0.5 mL/min for 3 h at room temperature. The monolith was then removed from the
column housing and ground to a fine powder through the use of a mortar and pestle. The
powder was placed on a watch glass and placed in a vacuum oven overnight at room
temperature to remove all water. The same procedure was used for control monoliths that
were prepared under identical conditions to those used for the HSA supports but with no
protein being added during the immobilization step. All samples were analyzed in triplicate
by using the BCA assay, with soluble HSA being employed as the standard and the control
support with no HSA present being utilized as the blank.
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Some representative monoliths were also characterized through the use of SEM. The
samples for these studies were polymerized and placed into column housings as described
earlier. Each support was then washed with 100 mL acetonitrile at 0.5 mL/min for 3 h after
polymerization. The monoliths were removed from their column housings and sliced into
thin disks through the use of a razor blade. The samples were placed on a watch glass and
dried under vacuum at 100 °C for 8 days. Prior to imaging, chromium was used to sputter
coat the samples for a period of 5 min.
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The chromatographic studies were performed at room temperature using pH 7.4, 0.067 M
potassium phosphate buffer as the mobile phase. The mobile phase was degassed and
sonicated for approximately 30 min prior to use. The sample consisted of 20 μM racemic
warfarin or racemic tryptophan in pH 7.4, 0.067 M potassium phosphate buffer, which was
injected in triplicate using a 20 μL loop and a flow rate of 0.1–1.0 mL/min. Sodium nitrate
was used as a void marker, with a 20 μL injection being made of 0.2 mM sodium nitrate.
The elution of R- and S-warfarin was monitored at 308 nm; the elution of D- and Ltryptophan was monitored at 280 nm; and the sodium nitrate was detected at 205 nm. No
significant amount of non-specific binding was observed for R/S-warfarin or D/L-tryptophan
to the monoliths in the absence of any immobilized HSA, as noted in previous studies with
similar supports [5]. The extra-column void time was measured by injecting sodium nitrate
onto the HPLC system with a zero dead volume connector being used in place of a column.

3. Results and discussion
3.1. Optimization of GMA/EDMA monoliths
The general procedure used in this report to make GMA/EDMA monoliths was modified
from a previous method that had been optimized for IgG and later used directly for HSA
[3,5]. To optimize this procedure for HSA, several parameters were considered, but an
emphasis was placed on the composition of the porogen (i.e., the mixture of 1-dodecanol
plus cyclohexanol). Altering the porogen composition was of interest because it has been
shown to be a convenient route for varying the pore structure, morphology and surface area
that is available for protein immobilization in GMA/EDMA monoliths [3].
Two types of GMA/EDMA monoliths were considered in this study, as based on previous
work with various proteins [3,5,7]. The conditions used for making these monoliths are
J Chromatogr A. Author manuscript; available in PMC 2013 December 21.
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summarized in Tables 1s and 2s in the Supplemental Materials. One set of thirteen
monoliths, each made in triplicate, was prepared at 60 °C with the amount of monomers
versus porogen being held at a 40:60 (v/v) ratio and the relative amounts of GMA and
EDMA in this mixture being kept at 20:20 (v/v). A second set of thirteen monoliths was
prepared at 80 °C and with the amount of monomers versus porogen again being kept at a
40:60 (v/v) ratio, but with the amount of GMA and EDMA now being 24:16 (v/v). For each
set of monoliths, the ratio of 1-dodecanol to cyclohexanol was varied from 4:56 to 52:8 (v/v)
of the total polymerization mixture (i.e., levels corresponding to a 1-dodecanol content of
6.7–86.7% in the porogen). Both the Schiff base and epoxy immobilization methods were
used to attach HSA to these supports. A large excess of HSA (i.e., greater than 10-fold
versus the final immobilized protein content) was applied to ensure that the maximum
coverage was obtained.
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Fig. 3 illustrates how the amount of HSA that could be immobilized to each type of
monolith varied as the amount of 1-dodecanol versus cyclohexanol was altered in the
polymerization mixture. The overall trend was similar to what has been seen in prior work
for monoliths containing IgG, in which a maximum amount of immobilized protein is
obtained at intermediate amounts of 1-dodecanol [3]. The reason for the lower protein
content at large amounts of 1-dodecanol is that these conditions produce a monolith with
large pores and a low surface area for ligand attachment. As the amount of 1-dodecanol
versus cyclohexanol is decreased to intermediate levels, the overall pore size decreases and
the surface area of the material increases, leading to an increase in the amount of protein that
can be immobilized. However, a further decrease in the 1-dodecanol versus cyclohexanol
levels eventually leads to the creation of pores that are too small for the protein to enter, thus
leading to a smaller amount of immobilized protein [3].
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The amount of 1-dodecanol needed to reach the maximum HSA content for the GMA/
EDMA monoliths also depended on the polymerization temperature and monomer
composition. As shown inFig. 3, the amount of 1-dodecanol that gave the highest amount of
immobilized HSA for monoliths prepared at 60 °C and using 20:20 GMA/EDMA was
roughly 17% of the porogen (i.e., 10% of the total polymerization mixture). For monoliths
that were prepared at 80 °C and using 24:16 GMA/EDMA, this amount of 1-dodecanol was
approximately 33% of the porogen (i.e., 20% of the total polymerization mixture). This shift
could be explained based on the presence of possible differences in the pore structures and
surface areas of these two sets of supports (see Fig. 4(a) and (b) and Ref. [3]). Similar trends
in monoliths when changing the polymerization temperature and monomer composition
have been noted in prior work with GMA/EDMA monoliths [3,7]. In addition, the monoliths
prepared at 60 °C and using 20:20 GMA/EDMA resulted in a 53–57% lower maximum
HSA content than the monoliths that were prepared at 80 °C using 24:16 GMA/EDMA.
The relative amount of HSA that could be immobilized to these monoliths followed the
same trend for the epoxy and Schiff base methods, as can be seen by comparing Fig. 3(a)
and (c) with Fig. 3(b) and (d). The maximum amount of HSA that was immobilized by the
Schiff base method for monoliths that were prepared at 80 °C and using 24:16 GMA/
EDMA, as obtained with 33.3% 1-dodecanol in the porogen (i.e., 20% of the total
polymerization mixture), was 51.6 (±0.6) mg HSA/g monolith. Using the same type of
monolith with the epoxy immobilization method gave an HSA content of 32.2 (±1.8) mg
HSA/g monolith. In comparison, the monoliths that were prepared with the Schiff base
method, a polymerization temperature of 60 °C and using 20:20 GMA/EDMA with 16.7%
of 1-dodecanol in the porogen (i.e., 10% of the total polymerization mixture) gave a protein
content of 27.1 (±1.2) mg HSA/g monolith. The same monolith with the epoxy
immobilization method resulted in an HSA content of 18.1 (±1.7) mg HSA/g monolith.
Overall, the Schiff base method produced a 46–60% larger maximum amount of
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immobilized HSA for these supports when compared to the epoxy immobilization method.
A similar difference in the results for these immobilization methods was observed for the
GMA/TRIM monoliths that were examined later in this report. This difference has been
noted for these two coupling methods with other types of supports and is believed to be due
to the different rates of these immobilization processes and the relative stabilities of their
activated sites (e.g., hydrolytic loss of activated sites in the epoxy method over time)[5,7].
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The polymerization and immobilization conditions that gave the highest content of HSA
were also found to allow for the production of columns with relatively low back pressures.
This observation agrees with previous studies that have examined similar GMA/EDMA
supports [3,5,7]. The back pressure was typically less than 3.4 MPa (500 psi) at 0.5 mL/min
for a 4.6 mm i.d. × 50 mm HSA column prepared under the final conditions selected for use
with polymerization at 80 °C and using 24:16 GMA/EDMA, and was 1.4 MPa (200 psi) or
less for columns prepared at 60 °C and using 20:20 GMA/EDMA. Similar trends were noted
for these materials when they were utilized with 4.6 mm i.d. × 1 mm disk columns, giving
back pressures at 0.5 mL/min that were less than 0.3 MPa (50 psi) and 0.2 MPa (30 psi),
respectively. The difference in back pressure between these two sets of materials was
probably related to the smaller average pore size of the monoliths that were prepared at 80
°C and using 24:16 GMA/EDMA. However, the measured back pressures indicated that all
of these materials were suitable for use in HPLC systems for chiral separations or other
applications of HPAC and AMC.
3.2. Optimization of GMA/TRIM monoliths
Similar studies to those described for the GMA/EDMA monoliths were conducted with
GMA/TRIM monoliths. TRIM was of interest as an alternative monomer to EDMA in
monolith preparation because it offered the potential to produce a higher degree of crosslinking, thus increasing the potential for functional groups to be present on the surface of the
monolith [6,15]. Two sets of thirteen monoliths were prepared using 28:12 (v/v) GMA/
TRIM at 60 °C or 80 °C and with various amounts of 1-dodecanol versus cyclohexanol
being placed in the porogen. The results are summarized in Fig. 5 and in Tables 3s and 4s in
the Supplemental Material. Some representative SEM images of these materials are
provided in Fig. 4(c) and (d).
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The overall trends seen for the GMA/TRIM monoliths in Fig. 5 were similar to those for the
GMA/EDMA monoliths in Fig. 3. For instance, the largest amount of HSA that could be
attached to these materials occurred at intermediate levels of 1-dodecanol versus
cyclohexanol in the porogen. The location of this optimum was higher at 60 °C for the
monoliths prepared with the 28:12 GMA/TRIM (i.e., occurring at roughly 22% 1-dodecanol
in the porogen, or 13% in the total polymerization mixture) when compared to data for the
20:20 GMA/EDMA monoliths made at the same temperature in Fig. 3 (i.e., a 1-dodecanol
content in the porogen of around 17%). However, the 1-dodecanol content that produced the
largest HSA content did not show any noticeable change in going from a polymerization
temperature of 60–80 °C for the GMA/TRIM monoliths.
The maximum HSA content for the GMA/TRIM monoliths was next determined. For the
GMA/TRIM monoliths that were polymerized at 60 °C and using 21.7% 1-dodecanol in the
porogen, the Schiff base method gave supports that contained 48.8 (±2.0) mg HSA/g
monolith. Use of the epoxy method with the same type of support gave a 41% lower content
of 28.8 (±0.8) mg HSA/g monolith. Similar results were found for the GMA/TRIM
monoliths that were made at 80 °C and that also used 21.7% 1-dodecanol in the porogen. In
this case, the Schiff base method gave 46.3 (±1.5) mg HSA/g monolith, and the epoxy
method gave a 42% lower content of 27.2 (±1.3) mg HSA/g monolith. These protein
contents were between those measured earlier for monoliths prepared at 60 °C using 20:20
J Chromatogr A. Author manuscript; available in PMC 2013 December 21.
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GMA/EDMA and at 80 °C using 28:12 GMA/EDMA, the latter of which gave the highest
overall HSA content in this study.
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A set of 4.6 mm i.d. × 50 mm columns with HSA immobilized in GMA/TRIM monoliths
polymerized at 60 °C and using 21.7% 1-dodecanol in the porogen gave an average back
pressure of less than 2.0 MPa (300 psi) at 0.5 mL/min. Similar columns made with GMA/
TRIM monoliths prepared at 80 °C and using 21.7% 1-dodecanol in the porogen also gave a
back pressure of 2.0 MPa or less under these experimental conditions. Disk columns made
with these materials and that were 4.6 mm i.d. × 1 mm in size gave an average back pressure
less than 0.3 MPa (50 psi) at 0.5 mL/min. These properties indicated that such monoliths
would be suitable for use in HPLC systems for chiral separations and HPAC.
3.3. Comparison with previous studies
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Although the composition of GMA/EDMA or GMA/TRIM monoliths has not been
optimized in prior work with HSA, a previous report has examined the preparation of GMA/
EDMA monoliths for rabbit IgG [3]. Rabbit IgG has a larger mass and size than HSA (molar
mass, 150 kDa versus 66.5 kDa). This size change would be expected to lead to some
differences in the amount of surface area that is accessible to each of these proteins on a
porous polymer. It has been determined for IgG that the optimum polymerization conditions
for GMA/EDMA monoliths occur at a polymerization temperature of 80 °C when using
24:16 GMA/EDMA and roughly 30% 1-dodecanol in the porogen [3]. This resulted in
GMA/EDMA monoliths that could contain 59 (±3) mg IgG/g monolith, or 390 (±20) nmol/
g, when using the epoxy immobilization method. When the same conditions were applied to
HSA without further optimization, the amount of protein that was immobilized by the Schiff
base method was 282 (±19) nmol HSA/g monolith, or 19 (±1) mg/g [5].
As shown in Fig. 3, it was found there was a relatively sharp maximum in the amount of
HSA that can be immobilized to GMA/EDMA monoliths as the amount of 1-dodecanol in
the porogen was varied. Optimizing the level of 1-dodecanol in this region to 33% of the
porogen at a polymerization temperature of 80 °C and using 24:16 GMA/EDMA resulted in
51.6 (±0.6) mg HSA/g monolith, or 776 (±9) nmol/g, now being obtained by the Schiff base
method. This increase corresponded to over a 2.7-fold larger amount of HSA than could be
placed in a GMA/EDMA monolith when compared to the conditions that were used in Ref.
[5]. In a similar manner, the GMA/TRIM monoliths that were optimized in this report gave
up to a 2.6-fold higher HSA content than previous GMA/EDMA monoliths that have been
used for this protein [5].
3.4. Chromatographic studies of monoliths
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The next stage of this study employed the HSA monoliths that were optimized in this report
and explored their use in chiral separations. R/S-Warfarin was one chiral analyte that was
considered. Warfarin is an important anti-coagulant that is known to bind in a
stereoselective manner to Sudlow site I of HSA. This binding has led to the frequent use of
R- and S-warfarin as probes to examine and model the interactions of other drugs and
solutes at Sudlow site I and to evaluate HSA columns for chiral separations [18,25,26].
The chromatographic experiments were first conducted by utilizing a 4.6 mm i.d. × 50 mm
GMA/EDMA monolith that was made using 24:16 GMA/EDMA, 33% 1-dodecanol in the
porogen, and a polymerization temperature of 80 °C, with HSA being immobilized to the
resulting support by the Schiff base method. These were the conditions found in Figs. 3 and
5 to give the largest final protein content, with a value of around 52 mg HSA/g monolith. A
20 μL portion of 20 μM R/S-warfarin was then injected onto this column in the presence of
pH 7.4, 0.067 M potassium phosphate buffer at various flow rates. An example of a typical
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chromatogram that was obtained at 0.75 mL/min is shown in Fig. 6. The retention factor for
R-warfarin (kR) on the optimized column under these conditions was 81 (±1), and the
retention factor for S-warfarin (kS) was 121 (±2). The plate numbers measured for these two
peaks were both around 420–425, which corresponded to a total plate height of 0.12 mm.
Greater than baseline resolution (Rs = 1.71 (±0.04)) was produced between the warfarin
enantiomers in this example even though no organic modifiers were used to sharpen the
peaks or to modify the separation in this particular experiment (i.e., a relatively common
practice in protein-based chiral separations) [21–23,26]. The separation factor (α) for these
peaks was 1.49 (±0.03), where α represented the ratio of the retention factors (α= kS/kR).
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For comparison, the same separation conditions and samples were used with an HSA GMA/
EDMA monolith that was prepared as described in Ref. [5]. The results are also shown in
Fig. 6. The retention factors for R- and S-warfarin for this second, reference column were 37
(±2) and 55 (±1). The separation factor in this case was essentially the same as for the
optimized HSA monolith, giving a value for α of 1.48 (±0.03); however, the resolution was
now 1.49 (±0.03). The higher retention and resolution of the optimized HSA monolith were
both directly related to the 2.7-fold higher protein content of this column when compared to
the column based on Ref. [5]. This also explains why similar separation factors were
observed for the two columns, because the value of α would have normalized for any actual
or apparent differences in protein content when using analytes such as R- and S-warfarin
that bind to the same region of HSA [5,26].
Both columns in Fig. 6 allowed for essentially baseline resolution (i.e., a resolution of 1.5 or
greater) when using only an aqueous mobile phase with no organic additives. However, the
HSA monolith that was prepared according to Ref. [5] could not be used at higher flow rates
without leading to some overlap in the peaks and less than baseline resolution. This was not
the case for the newer, optimized HSA monolith. As shown in Fig. 7(a), this new type of
HSA support could be used at flow rates up to 1.5 mL/min and still provided essentially
baseline resolution between R- and S-warfarin. Thus, one result of having a higher content
of HSA in this monolith was that a chiral separation for R- and S-warfarin could be obtained
that was two times faster than seen for the same column in Fig. 6.
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It was also possible to increase the resolution and efficiency of the newer, optimized HSA
monolith by placing a small amount of an organic modifier into the mobile phase. For
instance, the addition of 0.5% 1-propanol to the mobile phase and the use of a flow rate of
0.75 mL/min gave retention factors on this column of 91 (±2) and 185 (±1) for R- and Swarfarin, with a resolution and separation factor that increased to 2.91 (±0.04) and 2.02
(±0.02), respectively. This increase in resolution was due to both a shift in the relative
retention of the enantiomers as well as the creation of narrower peaks, which now gave plate
numbers of 530–615 and plate heights of 0.08–0.09 mm.
A second experiment was completed in which D/L-tryptophan was used as a model analyte. LTryptophan is often used as a probe for the Sudlow site II of HSA [18], and D- and Ltryptophan are known to bind in a stereoselective manner to HSA [27], making these
enantiomers useful models in the initial evaluation of HSA columns for chiral separations.
The same HSA monolith as used in Fig 7(a) for R- and S-warfarin was tested for use in the
separation of D- and L-tryptophan. The results are provided in Fig. 7(b). At 1.5 mL/min, the
retention factor for D-tryptophan was 1.49 (±0.05) and for L-tryptophan it was 5.98 (±0.04).
The plate numbers that were obtained for these peaks were 430 and 270, respectively, which
gave total plate heights of 0.11 and 0.18 mm. The corresponding separation occurred in less
than 4 min, giving a resolution of 4.52 (±0.05) and a separation factor of 4.01 (±0.02). These
results indicated that the same type of optimized HSA monolith could be used in even
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smaller columns and/or at higher flow rates to further reduce the time of this separation
while still providing baseline resolution between the tryptophan enantiomers.
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As was noted for R/S-warfarin, an improvement in the resolution and efficiency of the new
HSA monoliths could be obtained for D- and L-tryptophan when adding a small amount of
organic modifier to the mobile phase. For instance, at 0.75 mL/min the use of 0.5% 1propanol in the mobile phase gave retention factors of 2.02 (±0.03) for D-tryptophan and
8.51 (±0.05) for L-tryptophan. The separation of these enantiomers again took place in less
than 4 min but now gave a resolution of 5.62 (±0.02) and a separation factor of 4.21 (±0.01).
The number of plates was 695 or 380 for D- and L-tryptophan under these conditions, which
corresponded to a total plate height of 0.07 or 0.13 mm.
3.5. Use of monoliths in affinity microcolumns
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The final stage of this report examined the use of the improved HSA monoliths in affinity
microcolumns for chiral separations or for the rapid screening of drug–protein binding.
These studies were carried out by using the same polymerization and immobilization
conditions as employed in the previous section (i.e., an HSA monolith made using 24:16
GMA/EDMA, 33% 1-dodecanol in the porogen, and a polymerization temperature of 80 °C,
with HSA being immobilized by the Schiff base method). However, the final monolith in
this case now had a size of 4.6 mm i.d. × 10 mm. This column exhibited a back pressure of
roughly 0.6 MPa (90 psi) at 0.5 mL/min when using pH 7.4, 0.067 M phosphate buffer as
the mobile phase.
This small monolith was evaluated by again using R/S-warfarin and D/L-tryptophan as model
chiral solutes. Flow rates up to 3 mL/min were used with D/L-tryptophan and up to 2.0 mL/
min were used with R/S-warfarin, as made possible by the lower back pressure of the 4.6
mm i.d. × 10 mm monolith compared to the 4.6 mm i.d. × 50 mm monoliths in the previous
section. A mobile phase consisting of pH 7.4, 0.067 M phosphate buffer was used with this
column, with 0.5% 1-propanol being added as an organic modifier in the initial studies.
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Some examples of chiral separations that were obtained with this HSA microcolumn are
shown in Fig. 8. In the separation that is shown in Fig. 8(a), the retention factor for Rwarfarin on the HSA microcolumn was 71 (±1) and for S-warfarin the retention factor was
128 (±2). The separation factor that was produced for these enantiomers was 1.80 (±0.01)
and greater than baseline resolution was obtained in less than 6.0 min (Rs = 1.55 (±0.03)).
The efficiencies noted for R-warfarin and S-warfarin were similar in this system, giving a
total plate height of 0.05 mm and plate numbers of 190–195 at 2.0 mL/min. All of these
results indicated that 4.6 mm i.d. × 10 mm HSA affinity microcolumns could be
successfully used to separate the warfarin enantiomers. In addition, these columns could do
so in a total separation time that was 5–13-times faster than was obtained with the 4.6 mm
i.d. × 50 mm HSA columns used in Figs. 6 and 7. This decrease in separation time was a
result of the shorter retention times of the HSA microcolumns and their lower back
pressures, the latter of which allowed higher flow rates to be used in this separation.
A similar separation was carried out for D/L-tryptophan on the 4.6 mm i.d. × 10 mm HSA
microcolumn. Fig. 8(b) shows some typical results that were acquired at 3.0 mL/min when
using a mobile phase that consisted of pH 7.4, 0.067 M phosphate buffer plus 0.5% 1propanol as an organic modifier. Under these conditions, the retention factors for Dtryptophan and L-tryptophan were 1.75 (±0.05) and 7.90 (±0.03). The separation factor for
these enantiomers was 4.51 (±0.01). The total plate heights measured for D-tryptophan and Ltryptophan were 0.05 and 0.12 mm, which corresponded to plate numbers of 200 and 85 at
3.0 mL/min. Greater than baseline resolution of these enantiomers was obtained in less than

J Chromatogr A. Author manuscript; available in PMC 2013 December 21.

Pfaunmiller et al.

Page 11

1.5 min, with an estimated resolution of 3.10 (±0.01). These results confirmed that the HSA
microcolumn could also be used for the rapid separation of these chiral solutes.
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It was further found that the HSA microcolumn gave good separations for these compounds
in the presence of only pH 7.4, 0.067 M phosphate buffer and no organic modifier, as might
be used in drug–protein binding studies. The separation that was obtained under these
conditions at 2.0 mL/min gave retention factors for R- and S-warfarin of 44 (±1) and 78
(±1), with a separation factor of 1.76 (±0.02) and a resolution of 1.33 (±0.02). The total plate
height for both warfarin enantiomers was 0.007 cm, which corresponded to 150 theoretical
plates. The retention factors measured for D- and L-tryptophan at 3.0 mL/min under the same
mobile phase conditions were 1.10 (±0.03) and 3.50 (±0.01), resulting in a separation factor
of 3.20 (±0.03) and a resolution of 2.90 (±0.02). The total plate heights for D-tryptophan and
L-tryptophan were 0.08 mm and 0.13 mm, respectively, with plate numbers of 135 and 75.

4. Conclusions
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This study examined and optimized GMA/EDMA and GMA/TRIM monoliths for the
immobilization of HSA as a chiral binding agent. The polymerization conditions used for
these monoliths were varied, with particular emphasis being given to the effects of changing
the composition of the porogen. Use of both the Schiff base and epoxy immobilization
methods with these monoliths was also considered. A 2.6–2.7-fold increase in HSA content
was obtained in the final monoliths when compared to similar HSA monoliths prepared
according to the literature. The increased protein content made it possible for the new
monoliths to provide fast separations with good retention and resolution for chiral agents
such as R/S-warfarin and D/L-tryptophan. It was further demonstrated that the final optimized
monoliths could be used in 4.6 mm i.d. × 10 mm HSA microcolumns to separate these chiral
solutes in only 1.5–6.0 min. Areas in which these monoliths should be useful include not
only fast chiral separations but also rapid HPAC studies of drug–protein interactions
involving HSA, as could be used for high-throughput drug screening [18,28–31]. In
addition, the approaches used in this study could be extended to the separation of other
chiral solutes and to the optimization of organic monoliths for use with other proteins as
binding agents.
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Fig. 1.

General scheme for the preparation of (top) GMA/EDMA monoliths and (bottom) GMA/
TRIM monoliths.
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Fig. 2.
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The (a) Schiff base and (b) epoxy immobilization methods.
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Fig. 3.
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Effects of varying the porogen composition on the amount of HSA that could be attached to
GMA/EDMA monoliths prepared at 60 °C and utilizing (a) the epoxy method or (b) Schiff
base method for immobilization; and to GMA/EDMA monoliths prepared at 80 °C and
using (c) the epoxy method or (d) Schiff base method for immobilization. The error bars
represent a range of ±1 standard deviation of the mean for triplicate measurements.
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Fig. 4.

Scanning electron micrographs for monoliths polymerized (a) at 80 °C using 24:16 GMA/
EDMA and 40:20 cyclohexanol:1-dodecanol in the polymerization mixture; (b) at 60 °C
using 20:20 GMA/EDMA and 50:10 cyclohexanol:1-dodecanol in the polymerization
mixture; (c) at 80 °C using 28:12 GMA/TRIM and 47:13 cyclohexanol:1-dodecanol in the
polymerization mixture; or (d) at 60 °C using GMA/TRIM and 47:13 cyclohexanol:1dodecanol in the polymerization mixture. Other conditions are given in the text.
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Fig. 5.
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Effect of varying the porogen composition on the amount of HSA that could be attached to
GMA/TRIM monoliths prepared at 60 °C and utilizing (a) the epoxy method or (b) Schiff
base method for immobilization; and to GMA/TRIM monoliths prepared at 80 °C and
utilizing (c) the epoxy method or (d) Schiff base method for immobilization. The error bars
represent a range of ±1 standard deviation of the mean for triplicate measurements.
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Fig. 6.
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Chiral separation of R- and S-warfarin on 4.6 mm i.d. × 50 mm GMA/EDMA monolith
columns. The lower chromatogram was obtained for a column that was prepared under the
same conditions as used in Ref. [5] but using conditions which had optimized for IgG rather
than HSA. The upper chromatogram shows the results that were obtained using the
conditions that were optimized in this current study for HSA, which involved the use of a
mixture of 24:16 GMA:EDMA and 40:20 cyclohexanol:1-dodecanol that was polymerized
at 80 °C, followed by use of the Schiff base immobilization method. The mobile phase in
each case was pH 7.4, 0.067 M phosphate buffer and the flow rate was 0.75 mL/min. Other
conditions are given in the text.
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Fig. 7.

Chiral separations for (a) R- and S-warfarin and (b) D- and L-tryptophan on a 4.6 mm i.d. ×
50 mm GMA/EDMA monolith column, as prepared using the polymerization and
immobilization conditions that were optimized in this study for HSA (Note: see conditions
given in Fig. 6). The mobile phase was pH 7.4, 0.067 M phosphate buffer and the flow rate
was 1.50 mL/min. Other conditions are given in the text.
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Fig. 8.

Chiral separations for (a) R- and S-warfarin and (b) D- and L-tryptophan on a 4.6 mm i.d. ×
10 mm GMA/EDMA monolith column, as prepared using the polymerization and
immobilization conditions that were optimized in this study for HSA. The mobile phase was
pH 7.4, 0.067 M phosphate buffer that contained 0.5% 1-propanol. The flow rate in (a) was
2.0 mL/min and the flow rate in (b) was 3.0 mL/min. Other conditions are given in the text.
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